The Melanoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Melanoma: An Overview
As per the American Skin Association, Melanoma is a life-threatening Metastatic tumor that originates in cells called melanocytes, which are pigment-producing cells. The majority of melanomas are black or brown. However, some Melanomas are skin-colored, pink, red, purple, blue, or white. Melanoma begins on the skin where it is easy to see and treat. However, it can grow into the skin, reaching the blood vessels and lymphatics, and can spread within the body to various organs when it can be fatal. If it is recognized and treated early, the chances of recovery are very good. But if it is not found early, it can grow deeper into the skin and spread to other parts of the body. Once Melanoma spreads beyond the skin to other parts of the body, it becomes hard to treat and can be fatal.
Over the past years, several therapies have been approved by the US Food and Drug Administration (FDA). Depending on the features of the tumor (location, stage, and genetic profile), the therapeutic options may be surgical resection, chemotherapy, radiotherapy, photodynamic therapy (PDT), immunotherapy, or targeted therapy.
Melanoma Market Key Facts
-
Melanoma of the skin represents 5.6% of all new cancer cases in the U.S., with the rate of new cases of melanoma of the skin was 22.7 per 100,000 per year. The death rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths.
-
As per the National Cancer Institute, in 2020, an estimated 6,850 persons died from melanoma in the United States. For melanoma of the skin, death rates are higher among the middle-aged and elderly. More than 65% of the deaths due to Melanoma are between the age group of 55 to 85 years.
-
As per Cancer Research UK, melanoma is the fifth most common cancer in the UK. There are around 16,200 new melanoma skin cancer cases in the UK every year. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035.
-
As per DelveInsight, Melanoma is more prominent in males than females.
The Melanoma market size is anticipated to increase during the study period owing to the increase in the research and development programs related to Melanoma in recent years. The launch of emerging therapies will also boost the market growth.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Melanoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Melanoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Melanoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Melanoma Epidemiology Segmentation
-
Incident cases of Melanoma
-
Type-specific cases Melanoma
-
Stage-specific incident Cases of Melanoma
-
Mutation-specific (BRAF, MEK) incident Cases of Melanoma
-
Age-specific incident Cases of Melanoma
Melanoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Melanoma market or expected to get launched during the study period. The analysis covers Melanoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Melanoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/melanoma-market
Melanoma Therapeutics Analysis
The treatment of Melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of melanoma comprises immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. However, surgery is also considered an option in some instances.
As per DelveInsight, the Melanoma market dynamic is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, and incremental healthcare spending across the world.
Some of the key companies in the Melanoma Market include-
-
Aim ImmunoTech
-
Bristol Myers Squibb
-
Evelo Biosciences
-
Hemispherx Biopharma
-
Idera Pharmaceuticals
-
Immutep
-
Infinity Pharmaceuticals
-
Iovance Biotherapeutics
-
Nektar
-
Immutep
-
Oncolys BioPharma
-
Partner Therapeutics
-
Spring Bank Pharmaceuticals
And Many Others
Melanoma Therapies Covered in the report include:
-
EDP1503
-
IMO-2125
-
OBP 301
-
LN-144
-
Ampligen
-
IPI-549 +Nivolumab
-
Leukine in combination with ipilimumab and nivolumab
-
Eftilagimod alpha (LAG-3Ig or IMP321)
And Many More.
The pipeline of Melanoma is quite robust with several products available in the developmental stage which are expected to launch during the forecast period.
Get More Detailed Insights Into the Emerging Therapies & Key Companies –
https://www.delveinsight.com/sample-request/melanoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Melanoma Competitive Intelligence Analysis
4. Melanoma Market Overview at a Glance
5. Melanoma Disease Background and Overview
6. Melanoma Patient Journey
7. Melanoma Epidemiology and Patient Population
8. Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Melanoma Unmet Needs
10. Key Endpoints of Melanoma Treatment
11. Melanoma Marketed Products
12. Melanoma Emerging Therapies
13. Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Melanoma Market Outlook (7 major markets)
16. Melanoma Access and Reimbursement Overview
17. KOL Views on the Melanoma Market.
18. Melanoma Market Drivers
19. Melanoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/melanoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
Postoperative Nausea and Vomiting (PONV) Market
DelveInsight’s “Postoperative Nausea and Vomiting (PONV) Market” research report provides a detailed overview of the disease, historical and forecasted epidemiology as well as the Postoperative Nausea and Vomiting (PONV) Market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/